跳至主要内容
临床试验/ITMCTR2024000215
ITMCTR2024000215尚未招募1 期

A randomized controlled study on the intervention of Shen Qi Yang Xin Formula in stable coronary heart disease

Xiyuan Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 至 75(—)
性别
All

入选标准

  • (1) Meet the diagnostic criteria for stable coronary artery disease, and Coronary CTA or coronary angiography shows a 50%-70% narrowing of the lumen diameter of at least one major branch;
  • (2) Coronary CTA within the past month shows CT-FFR >0.8;
  • (3) Meet the diagnostic criteria of Qi deficiency and blood stasis;
  • (4) Age 30-75 years old, no gender restriction;
  • (5) Volunteer to be tested and sign an informed consent form.

排除标准

  • (1) Acute myocardial infarction or coronary artery revascularization treatment within the last 30 days.
  • (2) Those who have one of the following diseases: a. Hypertension and still high blood pressure after treatment with antihypertensive drugs (systolic blood pressure =160mmHg, diastolic blood pressure =100mmHg); b. Severe malignant arrhythmia, pulmonary heart disease, rheumatoid artery disease, myocarditis, cardiomyopathy, aortic coarctation, pulmonary embolism and other serious diseases.
  • (3) Those with symptoms of chest pain associated with diseases such as hyperthyroidism, ervical spondylosis, bile-cardiac syndrome, esophageal hiatal hernia, neurosis, and menopausal syndrome.
  • (4) Those at risk of severe bleeding.
  • (5) Those with serum ghrelin or serum creatinine >3 times the upper limit of normal reference value.
  • (6) Those with severe hematologic diseases and malignant tumors.
  • (7) Those with one of the following contraindications to coronary CTA: a. Previous history of severe allergic reaction to contrast media; b. Patients who are unable to cooperate with scanning and breath-holding; c. Pregnant women, lactating women, or women of childbearing age with childbearing requirements; d. Clinical signs of life are unstable (e.g., acute myocardial infarction, decompensated heart failure, severe hypotension, etc.); e. Severe renal insufficiency.
  • (8) Persons who are mentally ill or have cognitive dysfunction.
  • (9) Hypersensitivity to the test drug.
  • (10) Participation in other clinical trials within the last 1 month, or oral administration of blood-activating and blood-stasis-relieving herbal preparations.
  • (11) Patients whose coronary CTA images are unavailable or of poor quality for plaque characterization or hydrodynamic analysis.

研究者

相似试验